Hemab Therapeutics
(NASDAQ) COAG
Hemab Therapeutics Financials at a Glance
Market Cap
$1.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$37.99
EPS (TTM)
$0.00
P/E Ratio
0.00
Dividend
$0.00
Beta (Volatility)
5.08 (High)
Dividend
$0.00
Beta (Volatility)
5.08 (High)
Price
$34.01
Volume
347,152.271
Open
$31.39
Price
$34.01
Volume
347,152.271
Open
$31.39
Previous Close
$33.89
Daily Range
$30.74 - $35.49
52-Week Range
$18.00 - $38.87
Estimated Earnings Date
Aug 20, 2026
Dividend
$0.00
Beta (Volatility)
5.08 (High)
Price
$34.01
Volume
347,152.271
Open
$31.39
Previous Close
$33.89
Daily Range
$30.74 - $35.49
52-Week Range
$18.00 - $38.87
Estimated Earnings Date
Aug 20, 2026
COAG News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Hemab Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
72
CEO
Benny Sorensen, MD, PhD
Website
www.hemab.comHeadquarters
Cambridge, MA 02142, US
COAG Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
36.18%
Return on Capital
N/A
Return on Assets
-32.81%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
46.71M
Volume
347.15K
Avg. Volume
347.52K
Financials (TTM)
Gross Profit
$0.00
Operating Income
-$23.61M
EBITDA
-$23.54M
Operating Cash Flow
-$21.58M
Capital Expenditure
-$112.00K
Free Cash Flow
-$21.70M
Cash & ST Invst.
$163.53M
Total Debt
$1.06M
Hemab Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.47BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$24.93M
N/A
Employees
59
N/A
Net Income
-$22.69M
N/A
EBITDA
-$23.54M
N/A
Quarterly Fundamentals
Total Cash
$163.53M
N/A
Total Debt
$1.06M
N/A
Accounts Receivable
$1.43M
N/A
Inventory
$0.00
N/A
Long Term Debt
$519.00K
N/A
Short Term Debt
$544.00K
N/A
Return on Assets
-32.81%
N/A
Return on Invested Capital
-38.09%
N/A
Free Cash Flow
-$21.70M
N/A
Operating Cash Flow
-$21.58M
N/A